Insmed Is the Russell 2000’s Top Stock Going into Reconstitution, As Its Focus on Rare Diseases Fuels Major Gains

Making drugs and gene therapies for a small population of patients might not sound all that appealing, but for InsmedINSM

, it’s the only game in town. Taking aim at rare diseases, the biotech standout is hoping to generate billions from selling treatments to meet the unmet needs of millions of patients, often left with few quality alternatives.

• Its first product, Arikayce, was approved in March for mycobacterium avium complex (MAC) lung disease, offering a last-line therapy for those with the chronic lung infection who are not responding to multidrug therapy.
• Insmed also made Fierce Pharma’s ‘most anticipated drug launches’ in early 2025 for brensocatib, targeting three neutrophil-driven conditions, with possible peak sales of $2.8B.

Getting over the hump: Despite its promise, Insmed’s aspirations in the lab still outstrip its revenue — which rose 23% to $92.8M in Q1, while its net loss reached $256M. To meet the demands of its clinical pipeline, it raised $1.4B last week on positive Phase 2 study data from its rising rare pulmonary disease candidate. The $19B outfit is eying gene therapies — but its star-studded lineup of potential blockbusters has already captured attention from investors, with the stock up 43% YTD. Ready to graduate from the top of the Russell 2000 to the middle of the Russell 1000, it might have also caught the eye of M&A-hungry pharmas, envious of its recent success.